特宝生物：9月4日召开董事会会议

Group 1 - The core point of the article is that 特宝生物 (Tebao Biotech) held its 11th meeting of the 9th Board of Directors on September 4, 2025, to discuss the proposal for granting reserved restricted stocks under the 2024 restricted stock incentive plan [1] - For the year 2024, the revenue composition of 特宝生物 indicates that 99.73% comes from biopharmaceuticals, while other businesses account for only 0.27% [1] - As of the time of reporting, 特宝生物 has a market capitalization of 34.5 billion yuan [1] Group 2 - The article also mentions 海底捞 (Haidilao) and its various ventures, highlighting that the survival rate of its sub-brands is less than 50% [1]